 

Active ingredient: Bromocriptine Mesylate 

 

Form/Route: Capsule/Oral 

 

Recommended studies: 1 study 

 

 Type of study: Fed 
Design: Single-dose, two-way, crossover in-vivo 

Strength: 5.0 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional Comments: 

_____________________________________________________________________________ 

 

Analytes to measure: Bromocriptine in plasma 

 

Bioequivalence based on (90% CI): Bromocriptine 

 

Waiver request of in-vivo testing: Not Applicable 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 

 


